Status:
UNKNOWN
High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)
Lead Sponsor:
University of Zurich
Conditions:
Pulmonary Vascular Disease
Pulmonary Artery Hypertension
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The investigators aim to study the effect of SOT in participants with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)...
Detailed Description
Participants with PVD diagnosed with precapillary PH with right heart catheterization and classified to groups 1 and 4 (PAH or CTEPH) who permanently live at HA \>2500 (PVDHA) will have 6-minute walk ...
Eligibility Criteria
Inclusion
- I
- Adult patients 18-80 years old of both genders,
- Residence \> 2500m of altitude
- diagnosed with precapillary PH (mean pulmonary artery pressure (mPAP) \>20 mmHg, pulmonary artery wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) ≥2 wood units (WU) by right heart catheterization) with PH being classified as PAH or CTEPH according to guidelines
- Patients stable on therapy
- New York Heart Association (NYHA) functional class I-III
- Provided written informed consent to participate in the study.
Exclusion
- Age \<18 years or \>80 years
- unstable condition
- Patients who cannot follow the study investigations, patient permanently living \< 2500m.
- Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, severe smokers (\>20 cigarettes/day)
- Severely hypoxemic patients at Quito permanently have persistent oxygen saturation by pulseoximetry (SpO2) \<80% on ambient air.
- Patients with chronic mountain sickness (Hemoglobin \> 19 g/dl in women, \>21 g/dl in men)
- Patient with a non-corrected ventricular septum defect
- Relevant concomitant other disease of the heart, kidney, liver, blood (anemia hemoglobin\<11 g/dl)
Key Trial Info
Start Date :
September 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06003244
Start Date
September 23 2023
End Date
December 31 2023
Last Update
October 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zürich
Zurich, Switzerland, 8091